Compare · ISPC vs SYNH
ISPC vs SYNH
Side-by-side comparison of iSpecimen Inc. (ISPC) and Syneos Health Inc. (SYNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ISPC and SYNH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- SYNH is the larger of the two at $9.19B, about 2132.3x ISPC ($4.3M).
- ISPC has hit the wire 6 times in the past 4 weeks while SYNH has been quiet.
- SYNH has more recent analyst coverage (19 ratings vs 2 for ISPC).
- Company
- iSpecimen Inc.
- Syneos Health Inc.
- Price
- $3.08-6.67%
- $42.98+0.01%
- Market cap
- $4.3M
- $9.19B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 6
- 0
- Recent ratings
- 2
- 19
Syneos Health Inc.
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
Latest ISPC
- iSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- iSpecimen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form DEFA14A filed by iSpecimen Inc.
- SEC Form D filed by iSpecimen Inc.
- iSpecimen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- E.F. Hutton & Co. Serves as Exclusive Placement Agent on iSpecimen Inc. $2.5 Million Private Placement
- iSpecimen Inc. Announces Pricing of Approximately $2.5 Million Private Placement
- iSpecimen Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- iSpecimen Inc. filed SEC Form 8-K: Other Events
- iSpecimen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest SYNH
- Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
- Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
- Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
- NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
- SEC Form 15-12G filed by Syneos Health Inc.
- Syneos Health Tapped PRA Health Sciences' Colin Shannon as the CEO Succeeding Michelle Keefe
- SEC Form 8-K filed by Syneos Health Inc.
- Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)
- Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)
- Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)